IN mid-2018, a diverse group of stakeholders urged the government to provide life-saving drug therapy for Malaysians devastated by a genetic disorder known as spinal muscular atrophy (SMA).
Close to 50 other countries provide a drug therapy using nusinersen (marketed as Spinraza), and many will soon also provide the gene medication onasemnogene abeparvovec (marketed as Zolgensma). We can expect a third drug therapy called Risdiplam to be filed for approval by the end of this year.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
